CTNNA1
CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer and Cervical cancer.
Overview
Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins.
Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes genetic literature 0.01, literature 0.92, genetic association 0.83, somatic mutation 0.43, animal model 0.60). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Cervical Adenocarcinoma, Colorectal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer and Cervical cancer.
- 1 · What it is
CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer and Cervical cancer.
- 2 · What goes wrong in cancer
Associates with the cytoplasmic domain of a variety of cadherins.
- 3 · How drugs use it
No product in this corpus aims at CTNNA1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:2509 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35221 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000044115 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: colorectal cancer 0.59, gastric cancer 0.63 (GraphQL API, CC0)); IntOGen CTNNA1 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. Location: Cytoplasm, cytoskeleton; Cell junction, adherens junction; Cell membrane; Cell junction (UniProt). Locus 5q31.2 (HGNC).
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.63 with gastric cancer (MONDO_0001056)
- Colorectal cancer: Open Targets association 0.59 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)
- Cervical cancer: IntOGen driver in 1 cohort (CEAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CTNNA1" OR ABSTRACT:"CTNNA1" OR TITLE:"catenin alpha 1" OR ABSTRACT:"catenin alpha 1" OR TITLE:"Catenin alpha-1" OR ABSTRACT:"Catenin alpha-1" OR TITLE:"CAP102" OR ABSTRACT:"CAP102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNNA1, not a curated reading list.